Active Ingredient History
Isatuximab, sold under the brand name Sarclisa, is a monoclonal antibody (mAb) medication for the treatment of multiple myeloma. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Amyloidosis (Phase 2)
Anemia, Hemolytic, Autoimmune (Phase 2)
Blood Protein Disorders (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1/Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Colorectal Neoplasms (Phase 1/Phase 2)
Constipation (Phase 2)
Cryoglobulinemia (Phase 2)
Diarrhea (Phase 2)
Eosinophils (Phase 2)
Gastrointestinal Hemorrhage (Phase 2)
Hematologic Diseases (Phase 2)
Hematologic Neoplasms (Phase 1/Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 2)
Hepatomegaly (Phase 2)
Immune System Diseases (Phase 1/Phase 2)
Immunoglobulin Light-chain Amyloidosis (Phase 2)
Kidney Failure, Chronic (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Lymphadenopathy (Phase 2)
Lymphoma (Phase 1/Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, T-Cell (Phase 2)
Macroglossia (Phase 2)
Multiple Myeloma (Phase 3)
Nausea (Phase 2)
Neoplasms (Phase 2)
Neoplasms by Histologic Type (Phase 2)
Neoplasms, Plasma Cell (Phase 2)
Paraproteinemias (Phase 2)
Prostatic Neoplasms (Phase 1/Phase 2)
Purpura (Phase 2)
Satiety Response (Phase 2)
Urinary Bladder Neoplasms (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
